Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2022 | The future of MS treatment and management

Raphael Schneider • 2 Mar 2022
ACTRIMS 2022
Multiple Sclerosis and Related Disorders

Raphael Schneider, MD, PhD, FRCPC, CIP, St. Michael’s Hospital, Toronto, Canada, comments on multiple sclerosis (MS) management shifting towards treating patients with radiologically isolated syndrome (RIS). Schneider mentions the potential to identify subgroups of patients with RIS who would benefit from therapeutic intervention, based on their MRI results and biomarkers, whilst others are observed and followed before being offered therapy. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.

More from Raphael Schneider

5:27
Assessing the peripheral immune compartment of patients with RIS
Raphael Schneider • 3 Mar 2022
1:03
Potential use of MRI sequencing in the clinical setting of MS
Raphael Schneider • 2 Mar 2022
1:30
Developments in biomarkers for MS susceptibility and prodrome
Raphael Schneider • 2 Mar 2022

Related Videos

3:44
Navigating intra-individual variability for early detection of cognitive decline
Leigh Charvet • 23 Feb 2024
5:42
Mapping the functional interactome in MS lesions to shed light on remyelination failure
Milos Opacic • 5 Mar 2024
3:26
Acupressure for the management of pain and anxiety in patients with MS
Megan Weigel • 4 Mar 2024
5:37
GAIT-HUB: a home-based gait monitoring system for patients with MS
Giuseppina Pilloni • 4 Mar 2024
The content of VJNeurology is intended for healthcare professionals